A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Phase 1/2 Terminated 56 enrolled Antengene Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE \[ifosfamide+carboplatin+etoposide\] or GEMOX \[gemcitabine+oxaliplatin\] or Tislelizumab), after treatments of 2 to 6 cycles transferring to ATG-010 monotherapy maintenance treatment, to evaluate the safety, tolerability, and primary efficacy of ATG-010 in R/R PTCL and NK/T-cell lymphoma patients.

Timeline

Start: 2020-08-18
Primary completion: 2025-12-30
Completion: 2025-12-30

Publications

Liu C, Li D, Gao Y, Zhang W, Guo Z, Zhao J, Huang H, Tao R. Selinexor plus tislelizumab in patients with relapsed/refractory NK/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial. Oncologist. 2026 Jul 11:oyag266. doi: 10.1093/oncolo/oyag266. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selinexor	Other / unclassified	40 mg	Oral
Subject	Selinexor	Other / unclassified	60 mg	Oral
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	5000 mg/m2	Intravenous
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Etoposide	Small molecule	100 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Ifosfamide	Small molecule	5000 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Background	Tislelizumab	Monoclonal antibody	200 mg	Intravenous

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications